This CME-certified prIME News webcast provides is an in-depth review of recent advances in the use of immunotherapy for the treatment of patients with head and neck cancers.
0.75 AMA PRA Category 1 Credit™
Jan 10, 2018
Jan 10, 2019
Looking Toward 2018—Where Are We Headed With Immunotherapy in Head and Neck Cancers?
Robert Haddad, MD
Robert Haddad, MDDana-Farber Cancer Institute
Boston, Massachusetts, United States
This educational activity is designed to meet the needs of medical oncologists and other healthcare professionals involved in the treatment of patients with head and neck cancers.
After completion of this educational activity, participants should be able to:
- Identify recent and emerging efficacy and safety data for immunotherapeutic strategies for the treatment of head and neck cancers
- Explain the important features of patient selection for immunotherapies
- Identify strategies to recognize and manage adverse events due to the use of immunotherapies
This educational activity is supported by a grant from Merck and Co, Inc.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is provided by prIME Oncology.
Method of Participation
Links to the posttest are available on the video player pages.
In order to receive credit, participants must successfully complete the online posttest with 75% or higher.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Dr Haddad has disclosed consulting fees from AstraZeneca, BMS, Celgene, Eisai, Genentech, Merck, and Pfizer. He also disclosed clinical trial support to his institution from AstraZeneca, BMS, Merck, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Briana Betz, PhD (scientific content reviewer/planner) – no relevant financial relationships
- Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.